Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Nektar Therapeutics's Business Segments
Nektar Therapeutics's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Non Cash Royalty Revenue Related to Sale of Future Royalties
Total Revenue
$ 10
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Non Cash Royalty Revenue Related to Sale of Future Royalties0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Non Cash Royalty Revenue Related to Sale of Future Royalties | $ 21 | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Non Cash Royalty Revenue Related to Sale of Future Royalties0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Non Cash Royalty Revenue Related to Sale of Future Royalties | $ 21 | - |
Description of Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California, that specializes in developing innovative drugs and therapies for cancer, chronic pain, and autoimmune diseases. The company was founded in 1990 by a team of scientists and experienced pharmaceutical executives with the goal of improving the lives of patients.
Nektar Therapeutics focuses on creating drug candidates using its proprietary technology platforms: PEGylation, Polymer Conjugation, and Permeation Enhancement. These platforms enable the company to create a wide range of therapeutic molecules with optimized pharmacokinetics and enhanced therapeutic profiles.
The PEGylation platform is based on the modification of drugs with polyethylene glycol (PEG), which prolongs the drug’s half-life in the body, reduces its toxicity, and improves its efficacy. The Polymer Conjugation platform uses proprietary polymer technologies to enhance the pharmacokinetics of the drugs, allowing for better tissue targeting and drug retention. The Permeation Enhancement platform enhances the bioavailability and efficacy of small molecule drugs.
Nektar Therapeutics has a diverse pipeline of products, ranging from cancer therapies to chronic pain treatments. One of their leading products is Onzeald, also known as etirinotecan pegol, a medication for the treatment of advanced breast cancer. This medication uses the PEGylation platform to improve its pharmacokinetics and has shown promising results in clinical trials.
Other products in Nektar Therapeutics’ pipeline include NKTR-214, a cancer immunotherapy, NKTR-358, a therapy for autoimmune diseases, and NKTR-102, a treatment for ovarian cancer. The company also has partnerships with major pharmaceutical companies such as Bristol-Myers Squibb and Takeda Pharmaceuticals, which help to advance and commercialize its drug candidates.
Overall, Nektar Therapeutics is a cutting-edge biopharmaceutical company that specializes in developing innovative therapies that help improve the lives of patients suffering from chronic illnesses. Using its proprietary technology platforms, the company has an impressive pipeline of drug candidates that have the potential to revolutionize the treatment of cancer, chronic pain, and autoimmune diseases.
Nektar Therapeutics focuses on creating drug candidates using its proprietary technology platforms: PEGylation, Polymer Conjugation, and Permeation Enhancement. These platforms enable the company to create a wide range of therapeutic molecules with optimized pharmacokinetics and enhanced therapeutic profiles.
The PEGylation platform is based on the modification of drugs with polyethylene glycol (PEG), which prolongs the drug’s half-life in the body, reduces its toxicity, and improves its efficacy. The Polymer Conjugation platform uses proprietary polymer technologies to enhance the pharmacokinetics of the drugs, allowing for better tissue targeting and drug retention. The Permeation Enhancement platform enhances the bioavailability and efficacy of small molecule drugs.
Nektar Therapeutics has a diverse pipeline of products, ranging from cancer therapies to chronic pain treatments. One of their leading products is Onzeald, also known as etirinotecan pegol, a medication for the treatment of advanced breast cancer. This medication uses the PEGylation platform to improve its pharmacokinetics and has shown promising results in clinical trials.
Other products in Nektar Therapeutics’ pipeline include NKTR-214, a cancer immunotherapy, NKTR-358, a therapy for autoimmune diseases, and NKTR-102, a treatment for ovarian cancer. The company also has partnerships with major pharmaceutical companies such as Bristol-Myers Squibb and Takeda Pharmaceuticals, which help to advance and commercialize its drug candidates.
Overall, Nektar Therapeutics is a cutting-edge biopharmaceutical company that specializes in developing innovative therapies that help improve the lives of patients suffering from chronic illnesses. Using its proprietary technology platforms, the company has an impressive pipeline of drug candidates that have the potential to revolutionize the treatment of cancer, chronic pain, and autoimmune diseases.
Nektar Therapeutics is a biopharmaceutical company dedicated to discovering and developing innovative medicines for a range of serious diseases, including cancer, autoimmune diseases, and chronic pain. The company operates through several key segments involving various products and investigational therapies designed to enhance treatment outcomes for patients. Below is a detailed examination of Nektars segments, products, and services:
1. Oncology
Nektar Therapeutics focuses heavily on developing therapies that leverage the immune system to combat cancer, as well as novel approaches to traditional cancer treatments. The prominent products and investigational therapies in this segment include:
- Bempegaldesleukin (NKTR-214): This investigational therapy is an immune-oncology agent designed to activate and expand tumor-infiltrating lymphocytes, leading to a more robust anti-tumor immune response. Its innovative mechanism involves selectively engaging the IL-2 pathway to stimulate immune activation, providing a novel means to boost T-cell activity against tumors. Bempegaldesleukin has shown promise across various cancer types, including melanoma and other solid tumors, as it is assessed in multiple clinical trials.
- NKTR-255: Another investigational therapy, NKTR-255 aims to promote the growth and survival of natural killer (NK) cells. NK cells are essential components of the innate immune system that can directly kill tumor cells. This therapy is being investigated to complement existing cancer treatments, potentially enhancing the overall efficacy of immunogenic vaccines and other therapies to improve patient outcomes.
- Etirinotecan pegol (NKTR-102): This is an injectable, long-acting formulation of the chemotherapy agent irinotecan. By utilizing a polymer-based delivery system, etirinotecan pegol maintains therapeutic levels of the drug over extended periods, simplifying the treatment regimen and minimizing the frequency of dosing. This can enhance tolerability and may lead to improved clinical effectiveness for patients with advanced solid tumors.
Immunology
The immunology segment of Nektar Therapeutics focuses on developing therapies to manage autoimmune diseases—conditions characterized by the immune system mistakenly attacking the body’s own tissues. Key products and investigational therapies include:
- NKTR-358: Targeted for the treatment of autoimmune diseases, NKTR-358 aims to boost the function of regulatory T cells (Tregs). These cells play a crucial role in modulating the immune response and maintaining tolerance to self-antigens. The therapy seeks to address the underlying dysregulation in autoimmune conditions such as systemic lupus erythematosus and psoriasis, providing a novel immunomodulatory approach.
- NKTR-181: Designed as a non-addictive alternative to traditional opioids, NKTR-181 is specifically formulated to provide effective pain relief with a reduced risk of addiction and other adverse effects common to opioid medications. By acting as a mu-opioid receptor agonist but with a unique mechanism of action, NKTR-181 aims to alleviate chronic pain without the respiratory depression often associated with opioid use.
Partnered Products
In addition to developing its own therapies, Nektar Therapeutics collaborates with other biopharmaceutical companies to advance combination therapies and leverage shared expertise. Notable partnerships include:
- Amgen Partnership: Nektar is working jointly with Amgen to create a combination therapy designed to enhance the efficacy of cancer treatment. This collaboration combines Amgens established antibody therapies with Nektars innovative immune-oncology agents, including bempegaldesleukin, to improve treatment outcomes for patients with cancer.
- Bristol-Myers Squibb Partnership: In another significant collaboration, Nektar is partnering with Bristol-Myers Squibb to develop a combination therapy that merges Bristol-Myers Squibbs immune checkpoint inhibitors with Nektar’s therapies, such as NKTR-214. This partnership aims to explore synergies in immune modulation to increase therapeutic efficacy across various oncology indications.
Conclusion
Nektar Therapeutics stands at the forefront of biopharmaceutical innovation, particularly in oncology and immunology. Its pipeline of investigational therapies not only showcases promising advances in treatment options for cancer, autoimmune diseases, and chronic pain but also emphasizes Nektars role as a crucial collaborator in the pharmaceutical industry. Through its commitment to developing novel therapies and forming strategic partnerships, Nektar Therapeutics aims to enhance patient outcomes and address unmet medical needs across a range of challenging health conditions.
1. Oncology
Nektar Therapeutics focuses heavily on developing therapies that leverage the immune system to combat cancer, as well as novel approaches to traditional cancer treatments. The prominent products and investigational therapies in this segment include:
- Bempegaldesleukin (NKTR-214): This investigational therapy is an immune-oncology agent designed to activate and expand tumor-infiltrating lymphocytes, leading to a more robust anti-tumor immune response. Its innovative mechanism involves selectively engaging the IL-2 pathway to stimulate immune activation, providing a novel means to boost T-cell activity against tumors. Bempegaldesleukin has shown promise across various cancer types, including melanoma and other solid tumors, as it is assessed in multiple clinical trials.
- NKTR-255: Another investigational therapy, NKTR-255 aims to promote the growth and survival of natural killer (NK) cells. NK cells are essential components of the innate immune system that can directly kill tumor cells. This therapy is being investigated to complement existing cancer treatments, potentially enhancing the overall efficacy of immunogenic vaccines and other therapies to improve patient outcomes.
- Etirinotecan pegol (NKTR-102): This is an injectable, long-acting formulation of the chemotherapy agent irinotecan. By utilizing a polymer-based delivery system, etirinotecan pegol maintains therapeutic levels of the drug over extended periods, simplifying the treatment regimen and minimizing the frequency of dosing. This can enhance tolerability and may lead to improved clinical effectiveness for patients with advanced solid tumors.
Immunology
The immunology segment of Nektar Therapeutics focuses on developing therapies to manage autoimmune diseases—conditions characterized by the immune system mistakenly attacking the body’s own tissues. Key products and investigational therapies include:
- NKTR-358: Targeted for the treatment of autoimmune diseases, NKTR-358 aims to boost the function of regulatory T cells (Tregs). These cells play a crucial role in modulating the immune response and maintaining tolerance to self-antigens. The therapy seeks to address the underlying dysregulation in autoimmune conditions such as systemic lupus erythematosus and psoriasis, providing a novel immunomodulatory approach.
- NKTR-181: Designed as a non-addictive alternative to traditional opioids, NKTR-181 is specifically formulated to provide effective pain relief with a reduced risk of addiction and other adverse effects common to opioid medications. By acting as a mu-opioid receptor agonist but with a unique mechanism of action, NKTR-181 aims to alleviate chronic pain without the respiratory depression often associated with opioid use.
Partnered Products
In addition to developing its own therapies, Nektar Therapeutics collaborates with other biopharmaceutical companies to advance combination therapies and leverage shared expertise. Notable partnerships include:
- Amgen Partnership: Nektar is working jointly with Amgen to create a combination therapy designed to enhance the efficacy of cancer treatment. This collaboration combines Amgens established antibody therapies with Nektars innovative immune-oncology agents, including bempegaldesleukin, to improve treatment outcomes for patients with cancer.
- Bristol-Myers Squibb Partnership: In another significant collaboration, Nektar is partnering with Bristol-Myers Squibb to develop a combination therapy that merges Bristol-Myers Squibbs immune checkpoint inhibitors with Nektar’s therapies, such as NKTR-214. This partnership aims to explore synergies in immune modulation to increase therapeutic efficacy across various oncology indications.
Conclusion
Nektar Therapeutics stands at the forefront of biopharmaceutical innovation, particularly in oncology and immunology. Its pipeline of investigational therapies not only showcases promising advances in treatment options for cancer, autoimmune diseases, and chronic pain but also emphasizes Nektars role as a crucial collaborator in the pharmaceutical industry. Through its commitment to developing novel therapies and forming strategic partnerships, Nektar Therapeutics aims to enhance patient outcomes and address unmet medical needs across a range of challenging health conditions.